CSF tau, Aβ42, and MHPG differentiate dementia with lewy bodies from alzheimer's disease

Journal of Alzheimer's Disease

Volumn 27, Issue 2, 2011, Pages 377-384

  Aerts, Marjolein B ^a   Esselink, Rianne A J ^a   Claassen, Jugen A H R ^a   Abdo, Wilson Farid ^a   Bloem, Bastiaan R ^a   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; amyloid ; cerebrospinal fluid; dementia with Lewy bodies; diagnosis; MHPG; neurotransmitter metabolites; tau

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; AMYLOID BETA PROTEIN[1-42]; HOMOVANILLIC ACID; NEUROTRANSMITTER; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITION; DEMENTIA; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LEWY BODY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY;

EID: 81855168400     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110482     Document Type: Article

References (39)

1. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R (2003) Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 74, 720-724. (Pubitemid 36628281)
2. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos MJ, O'Brien J, Playfer J, Reid W (2004) Dementia with Lewy bodies. Lancet Neurol 3, 19-28. (Pubitemid 38018924)
3. Brown DF (1999) Lewy body dementia. Ann Med 31, 188-196. (Pubitemid 29304456)
4. Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, Xu LO, Smith CD, Markesbery WR (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 257, 359-366.
5. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C, Wenning GK (2003) Movement disorders society scientific issues committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 18, 467-486. (Pubitemid 36656531)
6. Henriksen AL, St DC, Setter SM, Tran JT (2006) Dementia with Lewy bodies: Therapeutic opportunities and pitfalls. Consult Pharm 21, 563-575. (Pubitemid 44543624)
7. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 305, 673-678.
8. Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, Burn D, Ballard CG (2005) Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 66, 633-637. (Pubitemid 40733707)
9. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon LM, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385-393.
10. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ (2003) Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60, 1696-1702. (Pubitemid 37521622)
11. Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, Yebenes JG, Del ST (2003) Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 60, 1218-1222. (Pubitemid 37099626)
12. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Ruther E, Kornhuber J, Otto M, Wiltfang J (2006) CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 1177-1187.
13. Verbeek MM, De Jong D, Kremer HP (2003) Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurode-generative diseases. Ann Clin Biochem 40, 25-40. (Pubitemid 36051407)
14. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evalua-tion of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379. (Pubitemid 32217453)
15. Kanemaru K, Kameda N, Yamanouchi H (2000) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 54, 1875-1876. (Pubitemid 30428428)
16. Tschampa HJ, Schulz-Schaeffer W, Wiltfang J, Poser S, Otto M, Neumann M, Kretzschmar HA (2001) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 56, 576. (Pubitemid 32172899)
17. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL (2007) Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78, 1176-1181. (Pubitemid 350057277)
18. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CL (2002) Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73, 134-140.
19. Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, Edwardson JA, Ince P, Blessed G, Irving D (1991) Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci 640, 197-202.
20. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, Baudrexel S, Diederich NJ, Heiss WD, Hilker R (2010) Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74, 885-892.
21. Kanemaru K, Yamanouchi H (2002) Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease. J Neurol 249, 1125-1126. (Pubitemid 35002246)
22. Weiner MF, Risser RC, Cullum CM, Honig L, White C, JIII, Speciale S, Rosenberg RN (1996) Alzheimer's disease and its Lewy body variant: A clinical analysis of postmortem verified cases. Am J Psychiatry 153, 1269-1273. (Pubitemid 26334198)
23. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E (1993) Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 43, 1927-1934. (Pubitemid 23318857)
24. Perry EK, Marshall E, Thompson P, McKeith IG, Coller-ton D, Fairbairn AF, Ferrier IN, Irving D, Perry RH 1993) Monoaminergic activities in Lewy body dementia: Relation to hallucinosis and extrapyramidal features. J Neural Transm Park Dis Dement Sect 6, 167-177.
25. Brautigam C, Steenbergen-Spanjers GC, Hoffmann GF, onisi-Vici C, van den Heuvel LP, Smeitink JA, Wevers RA (1999) Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. Clin Chem 45, 2073-2078.
26. Folstein MF, Robins LN, Helzer JE (1983) The Mini-Mental State Examination. Arch Gen Psychiatry 40, 812.
27. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feld-man H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del ST, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872. (Pubitemid 43970103)
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
29. Abdo WF, De Jong D, Hendriks JC, Horstink MW, Kremer BP, Bloem BR, Verbeek MM (2004) Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord 19, 571-579.
30. De Jong D, Jansen RW, Kremer BP, Verbeek MM (2006) Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61, 755-758. (Pubitemid 44148364)
31. Mann DM, Lincoln J, Yates PO, Stamp JE, Toper S (1980) Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry 136, 533-541. (Pubitemid 10120395)
32. Ohara K, Kondo N, Ohara K (1998) Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease. Prog Neuropsychopharmacol Biol Psychiatry 22, 311-317. (Pubitemid 28126237)
33. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del TK, Wszolek ZK, Litvan I (2009) Neuropathological assessment of Parkinson's disease: Refining the diagnostic criteria. Lancet Neurol 8, 1150-1157.
34. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F (2001) CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 22, 77-78. (Pubitemid 33622091)
35. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttila T, Schapiro MB, Rapoport SI, Moller HJ, Davies P, Hampel H (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59, 1267-1272. (Pubitemid 34856379)
36. Guthrie B, Clark SA, McCowan C (2010) The burden of psychotropic drug prescribingin people with dementia: Apop-ulation database study. Age Ageing 39, 637-642.
37. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T (2010) Differential levels of a-synuclein, fj-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 81, 608-610.
38. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
39. Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, Burn D, Ballard CG (2005) Neuroleptic sensitivity in Parkinson's disease and Parkinsonian dementias. J Clin Psychiatry. 66, 633-637. (Pubitemid 40733707)